Connect with us

Business

Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar

Published

on

Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar


Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

Shares of the company closed more than 3% higher Thursday.

The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, rising from its previous outlook of $21.75 to $23 a share.

Eli Lilly said the guidance reflects President Donald Trump‘s existing tariffs as of Thursday, but does not include his threatened levies on pharmaceuticals imported into the U.S.

Mounjaro raked in $6.52 billion in revenue for the quarter, up 109% from the same period a year ago. That blew past the $5.51 billion that analysts were expecting, according to StreetAccount. 

Zepbound, which entered the market roughly two years ago, posted $3.59 billion in revenue for the third quarter. That’s up 184% from the year-earlier period and slightly ahead of the $3.5 billion that Wall Street was expecting, according to StreetAccount estimates.

David Ricks, chief executive officer of Eli Lilly & Co., during a news conference at Generation Park in Houston, Texas, US, on Tuesday, Sept. 23, 2025.

Mark Felix | Bloomberg | Getty Images

In an interview with CNBC on Thursday, Eli Lilly CEO Dave Ricks said the “real star here” of the quarter is tirzepatide, the active ingredient in Zepbound and Mounjaro. Both drugs are leading the U.S. market for obesity and diabetes, he said. 

Ricks said the quarterly beat was driven by “really strong international performance,” pointing to Mounjaro’s launch in China, Brazil and India earlier this year. 

“What we’re seeing is a global demand for this product,” he told CNBC’s “Squawk on the Street.”

On an earnings call Thursday, Ricks said Eli Lilly gained share in the injectable obesity and diabetes market for the fifth consecutive quarter. The company’s drugs account for nearly 6 out of 10 prescriptions within that class of medicines.

Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $7.02 adjusted vs. $5.69 expected
  • Revenue: $17.60 billion vs. $16.01 billion expected

The results come as Eli Lilly works to maintain its edge over chief rival Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.

The company posted third-quarter revenue of $17.60 billion, up 54% from the same period a year ago. 

Sales in the U.S. jumped 45% to $11.30 billion. Eli Lilly said that was driven by a 60% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of the drugs, the company said.

The pharmaceutical giant booked net income of $5.58 billion, or $6.21 per share, for the third quarter. That compares with net income of $970.3 million, or $1.07 per share, a year earlier. 

Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $7.02 per share for the second quarter.

The results underscore Eli Lilly’s strong advantage in the booming GLP-1 drug market.

The company has gained the majority market share over the last year, thanks to the strong profile of its weight loss and diabetes injections and a boost from its direct-to-consumer sales, among other efforts. Eli Lilly took another stride to boost access to Zepbound on Wednesday, partnering with Walmart to offer in-store pickup of discounted vials of the drug for cash-paying patients.

In the interview, Ricks said Eli Lilly plans to expand its direct-to-consumer and cash-pay offerings for its drugs.

The company is now betting on its closely watched experimental obesity pill, orforglipron, to solidify its dominance in the space, especially as Novo Nordisk and other drugmakers race to bring their own pills or next-generation injections to the market. 

“We’ve been ramping both production and planning for really a broad global rollout upon regulatory approval,” Ricks told CNBC, referring to orforglipron’s launch.

On Thursday, Novo Nordisk launched a rival bid for U.S. obesity biotech company Metsera, hijacking an offer from Pfizer as it races to catch up to Eli Lilly.

When asked about competition, Ricks said on the earnings call that “of course, everybody would like to be in our position, but we’re focused on defending it and mostly just executing the play we have.”



Source link

Business

Tariff row: GTRI’s 3-step plan for India to protect its interests; key remarks on Russian oil – The Times of India

Published

on

Tariff row: GTRI’s 3-step plan for India to protect its interests; key remarks on Russian oil – The Times of India


Global Trade Research Initiative (GTRI) has proposed a three-step strategy to safeguard India’s trade interests as discussions with the United States have stepped into the “advanced stage.The agency has suggested measures like scaling back Russian oil imports, seeking trade parity and resuming talks on fair terms.

‘Very Good…’: Trump Drops Major Russian Oil Reveal After Talks With Xi, Lauds India

Here’s what GTRI’s 3 step plan says:

1. Halting Russian oil imports under sanctions

According to the think tank, the first move should be to stop importing oil from Russian companies currently under US sanctions, specifically Rosneft and Lukoil, which together account for 57% of Russia’s crude output. GTRI said that continuing to source crude from these firms exposes India to potential secondary sanctions that could extend and affect critical infrastructure. The note cautioned that more secondary sanctions might be far more damaging than tariffs, as they could disrupt SWIFT access, dollar payments and essential digital systems, potentially paralysing operations across refineries, ports and banks.

2. Removal of additional tariffs

Once such imports are halted, the advisory body recommends India to “press Washington to withdraw the punitive 25% “Russian oil” tariff.” Scrapping the tariff would cut India’s duty burden in the US by half, from 50% to 25%, and improve export competitiveness.These additional duties were introduced on July 31 which the US called a “Russian oil” tariff, accusing India of fueling Moscow’s war machine. Since then, India’s overall duty burden in the US market has climbed to 50%, coinciding with a noticeable drop in exports, down 37% between May and September.

3. Starting on fair terms

Only after tariffs return to normal levels, GTRI suggested to “restart trade negotiations…only on fair, balanced terms.”The organisation said India should push for tariff parity with its other major trade partners by targeting average duties of roughly 15% and securing duty-free access for priority sectors such as textiles, gems and jewellery, and pharmaceuticals.Commerce minister Piyush Goyal has signalled progress on a bilateral trade agreement with the United States, saying that the negotiations have reached an “advanced stage”. The development aligns with US President Donald Trump’s recent hint that a deal with India may be imminent.According to a TOI report, the proposed trade agreement could bring down US tariffs on Indian exports from 50% to 15%. In return, India is expected to scale back purchases of Russian oil and increase energy imports from the United States, along with fulfilling other commitments.





Source link

Continue Reading

Business

‘Supply chain reliability’: Not Ukraine, Russia is now top sunflower oil supplier to India; how it happened – The Times of India

Published

on

‘Supply chain reliability’: Not Ukraine, Russia is now top sunflower oil supplier to India; how it happened – The Times of India


Even as Moscow’s crude dominates headlines, it’s not the only Russian oil flowing into India. Russia has now surpassed Ukraine to become India’s biggest supplier of sunflower oil, with shipments soaring twelvefold over the past four years, according to industry data cited by ET.

‘Very Good…’: Trump Drops Major Russian Oil Reveal After Talks With Xi, Lauds India

“Russia is the largest and most reliable source of sunflower oil in the world. We get advantage of supply chain reliability,” Sanjeev Asthana, CEO of Patanjali Foods and president of the Solvent Extractors’ Association of India (SEA) told ET.Back in 2021, Russian sunflower oil made up only around 10% of India’s total sunflower oil imports. By 2024, that share had jumped to 56%. India purchased 2.09 million tonnes of sunflower oil from Russia in the calendar year 2024, compared to just 175,000 tonnes in 2021.

How did the shift happen?

Before the war, Ukraine was India’s main supplier of sunflower oil, shipping nearly 90% of its agricultural exports through seaports. However, once the conflict began, Ukraine redirected most of its sunflower oil to European countries via road and rail after its access to Black Sea ports was blocked. Industry officials said this rerouting made shipments to India costlier and less predictable.Russia, meanwhile, continued exporting comfortably through its seaports, giving Indian buyers a more stable and assured supply route. “They were offering us competitive rates, which is the requirement of the Indian market,” said Sandip Bajoria, president of the International Association of Sunflower Oil.Exchanges between industry delegations from both countries in recent months have further strengthened the trade link.

India’s reliance on foreign oils

Sunflower oil is among India’s top three edible oils, yet less than 5% of what the country consumes is grown domestically. The country relies on imports to meet almost 60% of its cooking oil needs. Palm oil accounts for nearly half of that, followed by soyabean oil and sunflower oil. Farmers in the country scaled back sunflower cultivation in the 1990s, after cheaper imported oils began entering the market.Sunflower oil became popular once again in 2023 and 2024, when for the first time it became cheaper than palm oil, according to industry officials, cited by ET. The new pricing advantage helped Russian shipments narrow the market gap between sunflower oil and soyabean oil. “The share of sunflower oil was a distant third after soyabean oil. The Russian supplies have reduced this gap significantly,” Bajoria said.This turnaround may not hold through the year. Sunflower oil imports are expected to decline by about 13% because of a sharp price rise. “The overall imports of sunflower oil will decline this year as there is a premium of $150 per tonne on sunflower oil over the palm oil and soyabean oil,” Bajoria added. “However, the share of Russia will remain the same at around 55-60%.”In September, a delegation from SEA travelled to Russia to explore deeper trade cooperation.





Source link

Continue Reading

Business

Banking, GST, Aadhaar And Pension Rules Change from November 1: Here’s What To Know

Published

on

Banking, GST, Aadhaar And Pension Rules Change from November 1: Here’s What To Know


Follow News18 on Google. Join the fun, play QIK games on News18. Stay updated with all the latest business news, including market trendsstock updatestax, IPO, banking finance, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the News18 App to stay updated.



Source link

Continue Reading

Trending